A Phase 2 interventional study of Nivolumab and Ipilimumab in Mesothelioma, Malignant, sponsored by Bristol-Myers Squibb. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Mesothelioma, Malignant with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Mesothelioma, Malignant · China.
Among the 20 studies in Mesothelioma, Malignant with a site in China, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 2, and was the 7th registered.
339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.
Browse Mesothelioma, Malignant studies →11 of the 20 studies in Mesothelioma, Malignant with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–75
Beijing Biotech · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China, United States
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Suzhou Maximum Bio-tech Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 10 · Phase 3 1
First in 2015; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 39 across 271 interventional studies indexed under Mesothelioma, Malignant.
Median enrollment 37 across the 18 interventional studies, 258 across the 2 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 2 studies filed under Mesothelioma, Malignant — fewer than ten, so there is no comparison to draw.
2 of the studies in Mesothelioma, Malignant with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07510815Beijing BiotechDual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma | 2027-03-14 |
| NCT06566079InSilico Medicine Hong Kong LimitedStudy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Mesothelioma, Malignant with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Also known as: BMS-734016, Yervoy
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Overall Survival (OS)
Time frame: Up to 58 months
Objective Response Rate (ORR) by modified Response Evaluation Criteria in Solid Tumors (m-RECIST) by Investigator
Time frame: Up to 58 months
Progression Free Survival (PFS) by m-RECIST by Investigator
Time frame: Up to 58 months
Incidence of Adverse Events (AEs)
Time frame: Up to 58 months
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 58 months
Incidence of immune-related AEs
Time frame: Up to 58 months
Incidence of deaths
Time frame: Up to 58 months
Incidence of participants with laboratory abnormalities
Time frame: Up to 58 months
Ran from Jan 2022 to primary completion in Nov 2025, 45 months.
Of 48 phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 45 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab · Pemetrexed · Cisplatin · Carboplatin